Last reviewed · How we verify
Paclitaxel Micelles for Injection
Paclitaxel micelles stabilize microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division.
Paclitaxel micelles stabilize microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division. Used for Metastatic breast cancer, Non-small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | Paclitaxel Micelles for Injection |
|---|---|
| Sponsor | Shanghai Yizhong Pharmaceutical Co., Ltd. |
| Drug class | Taxane; microtubule stabilizer |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel is a taxane that binds to β-tubulin dimers within microtubules, promoting their assembly and preventing disassembly. This disrupts the dynamic instability of microtubules required for mitotic spindle formation and cell cycle progression, leading to G2/M phase arrest and apoptosis in cancer cells. The micellar formulation improves solubility and reduces hypersensitivity reactions compared to conventional paclitaxel.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Ovarian cancer
- Gastric cancer
Common side effects
- Neutropenia
- Peripheral neuropathy
- Anemia
- Alopecia
- Nausea and vomiting
- Hypersensitivity reactions
Key clinical trials
- Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer (PHASE3)
- A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma (PHASE2)
- Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors. (PHASE1)
- Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer (PHASE2)
- Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer (PHASE3)
- A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer (PHASE2)
- Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLC (PHASE2)
- Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: